A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
|Articles|May 10, 2004
Botulinum toxin shows promising results in refractory OAB
Known primarily for smoothing facial wrinkles, botulinumtoxin A (Botox) is gaining acceptance as a treatment option for refractoryoveractive and neurogenic bladder. The latest evidence comes from the Universityof Pittsburgh School of Medicine, where a 110-patient review of the off-labeluse of botulinum toxin for those indications produced promising resultsin terms of both safety and efficacy.
Advertisement
Advertisement
Related to this article
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Advertisement
Advertisement